$1 million grant to support manufacturing of COVID-19 treatments, vaccines at uOttawa, The Ottawa Hospital

Posted on Monday, November 9, 2020

Photo collage of Dr. Stewart and team

Clockwise from top left: Dr. Duncan Stewart, Dr. Bernard Thébaud, Dr. John Bell, Dr. David Courtman and Dr. Carolina Ilkow.

Researchers from the University of Ottawa and The Ottawa Hospital have been awarded $1,050,000 million from the Canada Foundation for Innovation to support facilities for manufacturing innovative treatments and vaccines for COVID-19.

The funding will support new equipment and infrastructure at The Ottawa Hospital’s Biotherapeutics Manufacturing Centre (BMC), which has been successfully manufacturing therapies using cells, genes and viruses for clinical trials in Canada and abroad for more than 10 years.

The funding will enhance the BMC’s ability to support projects related to COVID-19, including:

“Our Biotherapeutics Manufacturing Centre has already played a crucial role in launching more than 15 world-first clinical trials,” said Dr. Duncan Stewart, Executive Vice-President of Research at The Ottawa Hospital and a professor at the Department of Cellular and Molecular Medicine. “Today’s funding will now allow us to harness this success to help in the global fight against COVID-19.”

The funding was announced by the Canada Foundation for Innovation, as part of a national announcement of more than $28 million for infrastructure related to COVID-19 research.

For media inquiries:
Paul Logothetis
Media Relations Officer
Cell: 613.863.7221
plogothe@uottawa.ca

Back to top